The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma
- 24 October 2011
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 48 (2), 202-208
- https://doi.org/10.1016/j.ejca.2011.09.001
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examinationEuropean Journal Of Cancer, 2011
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With SunitinibJNCI Journal of the National Cancer Institute, 2011
- Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinomaAnnals of Oncology, 2011
- Pretreatment Neutrophil-to-Lymphocyte Ratio as an Independent Predictor of Recurrence in Patients With Nonmetastatic Renal Cell CarcinomaJournal of Urology, 2010
- Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?Cell Division, 2010
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Cancer-related inflammationNature, 2008
- The Baseline Ratio of Neutrophils to Lymphocytes Is Associated with Patient Prognosis in Advanced Gastric CancerOncology, 2007
- Novel approaches in the therapy of metastatic renal cell carcinomaWorld Journal of Urology, 2005